| Literature DB >> 27747929 |
E Mazzotta1, C Guglielmini1, G Menciotti1, B Contiero1, M Baron Toaldo2, M Berlanda1, H Poser1.
Abstract
BACKGROUND: Red blood cell distribution width (RDW) is a quantitative measurement of anisocytosis. RDW has prognostic value in humans with different cardiovascular and systemic disorders, but few studies have investigated this biomarker in dogs.Entities:
Keywords: Azotemia; Canine; Cardiac biomarker; Cardiovascular disease; Echocardiography
Mesh:
Substances:
Year: 2016 PMID: 27747929 PMCID: PMC5115192 DOI: 10.1111/jvim.14596
Source DB: PubMed Journal: J Vet Intern Med ISSN: 0891-6640 Impact factor: 3.333
Clinical data in 127 dogs
| Healthy (n = 19) | MMVD (n = 50) | PH‐MMVD (n = 32) | Precapillary PH (n = 26) | Overall | |
|---|---|---|---|---|---|
| Age (years) | 8.5 (7.1–10.4) | 10.8 (7.0–13.4) | 12.0 (11.0–14.1) | 12.0 (10.0–14.0) | <.001 |
| Body weight (kg) | 14.5 (9.0–28.0) | 9.9 (7.8–14.1) | 8.7 (7.0–10.9) | 10.5 (7.0–20.0) | .028 |
| Sex (male/female) | 7/12 | 28/22 | 20/12 | 10/16 | .15 |
| Drugs received (n) | NA | P (6) | ACE‐I (17) | ACE‐I (2) | |
| ACE‐I (5) | Fu (12) | P (2) | |||
| Fu (4) | P (7) | Ma (1) | |||
| Di (4) | Sp (1) | F (1) | |||
| Sp (4) | Si (1) | ||||
| Dt (1) | St (1) |
MMVD, Myxomatous mitral valve disease without pulmonary hypertension; PH‐MMVD, pulmonary hypertension associated with myxomatous mitral valve disease; PH = pulmonary hypertension; n, number of dogs; NA, not applicable; P, pimobendan; ACE‐I, angiotensin‐converting enzyme inhibitor; Fu, furosemide; Di, digoxin; Sp, spironolactone; Dt, diltiazem; Ma, maropitant; Si, sildenafil; St, steroids.
*P < .05 compared with healthy dogs.
**P < .01 compared with healthy dogs.
***P < .001 compared with healthy dogs.
Data are expressed as median (interquartile range).
Laboratory and echocardiographic data in 127 dogs
| Healthy (n = 19) | MMVD | Precapillary PH (n = 26) | Overall | ||
|---|---|---|---|---|---|
| MMVD (n = 50) | PH‐MMVD (n = 32) | ||||
| Hematology | |||||
| RDW (%) | 13.3 (12.3–13.7) | 13.5 (12.7–14.2) | 13.7 (13.2–14.7) | 13.8 (13.2–14.9) | .011 |
| Hematocrit (%) | 48.6 (45.6–50.5) | 45.5 (42.2–50.5) | 48.2 (41.2–51.8) | 48 (45–51.2) | .58 |
| Hemoglobin (g/dL) | 168 (160–172) | 157 (144–171) | 164 (141–175) | 162 (148–173) | .81 |
| MCV (fL) | 69.2 (66.7–70.7) | 68.3 (64.6–70.4) | 68.2 (65.0–70.3) | 68.9 (65.4–71.5) | .76 |
| WBC (109/L) | 7.4 (6.2–10.5) | 9.6 (7.5–11.0) | 12.2 (9.3–18.1) | 15.1 (10.0–25.3) | <.001 |
| Platelets (109/L) | 355 (262–403) | 339 (284–449) | 372 (315–460) | 405 (270–493) | .32 |
| Biochemistry | |||||
| Urea (mg/dL) | 29.0 (17.8–34.0) | 38.5 (28.0–44.0) | 47.0 (37.0–81.0) | 59.8 (33.0–81.5) | <.001 |
| Creatinine (mg/dL) | 0.94 (0.76–1.07) | 0.94 (0.81–1.11) | 1.23 (0.85–1.42) | 0.98 (0.83–1.26) | .11 |
| Total proteins (g/L) | 65.7 (62.6–71.2) | 61.4 (58.7–67.0) | 62.1 (57.5–68.5) | 69.2 (61.8–75.8) | .11 |
| Echo | |||||
| LVDDn | 1.54 (1.4–1.57) | 1.59 (1.46–1.72) | 2.16 (2.0–2.26) | 1.13 (0.87–1.43) | <.001 |
| LVSDn | 0.97 (0.93–1.00) | 0.91 (0.8–1.09) | 1.1 (0.94–1.23) | 0.66 (0.6–0.86) | <.001 |
| LA:Ao | 1.30 (1.20–1.40) | 1.50 (1.33–1.66) | 2.83 (2.45–3.36) | 1.38 (1.30–1.55) | <.001 |
| FS (%) | 34 (31–39) | 39 (33–44) | 48 (41–54) | 41 (27–46) | <.001 |
| E‐max (m/s) | 0.70 (0.58–0.83) | 0.74 (0.60–0.94) | 1.62 (1.39–1.81) | 0.57 (0.41–0.63) | <.001 |
| TR Vmax (m/s) | NA | 2.34 (1.92–2.62) | 3.46 (3.25–3.69) | 4.05 (3.46–4.61) | <.001 |
| TRPG (mmHg) | NA | 21.9 (14.7–27.4) | 47.9± (40.1–54.0) | 65.8 (47.8–85.0) | <.001 |
RDW, Red blood cell distribution width; MCV, mean corpuscular volume; WBC, white blood cell number; LVDDn, left ventricular diastolic diameter normalized for body weight; LVSDn, left ventricular systolic diameter normalized for body weight; LA, left atrial diameter; Ao, aortic diameter; FS, fractional shortening; E‐max, transmitral peak E‐wave velocity; TR Vmax, peak velocity of tricuspid regurgitation; TRPG, tricuspid regurgitation pressure gradient; n, number of dogs; MMVD, myxomatous mitral valve disease; PH‐MMVD, pulmonary hypertension associated with MMVD.
P < .05 compared with healthy dogs.
P < .01 compared with healthy dogs.
P ≤ .001 compared with healthy dogs.
P < .05 compared with dogs with MMVD.
P < .01 compared with dogs with MMVD.
P ≤ .001 compared with dogs with MMVD.
P < .05 compared with dogs with PH‐MMVD.
P < .01 compared with dogs with PH‐MMVD.
P ≤ .001 compared with dogs with PH‐MMVD.
Data are expressed as median (interquartile range).
Laboratory and echocardiographic data in 69 dogs without pulmonary hypertension (No PH), including healthy dogs and dogs with myxomatous mitral valve disease without PH, and 58 dogs with different degree of PH
| No PH (n = 69) | PH | Overall | |||
|---|---|---|---|---|---|
| Mild (n = 26) | Moderate (n = 20) | Severe (n = 12) | |||
| Hematology | |||||
| RDW (%) | 13.4 (12.7–14.0) | 13.7 (13.2–14.5) | 13.5 (13.0–14.8) | 14.5 (13.6–17.3) | .009 |
| Hematocrit (%) | 47.4 (44.3–50.5) | 49.7 (45.0–53.0) | 46.7 (40.4–51.4) | 48.0 (43.4–50.2) | .36 |
| Hemoglobin (g/dL) | 161 (146–171) | 166 (150–177) | 157 (134–173) | 163 (149–172) | .55 |
| MCV (fL) | 68.3 (65.5–70.6) | 68.2 (66.0–70.5) | 69.0 (65.3–70.9) | 67.7 (64.5–69.6) | .82 |
| WBC (109/L) | 8.7 (7.2–10.5) | 10.6 (8.7–17.3) | 15.9 (10.2–20.4) | 14.4 (11.7–37.0) | <.001 |
| Platelets (109/L) | 341 (277–429) | 399 (314–493) | 372 (270–491) | 385 (297–415) | .34 |
| Biochemistry | |||||
| Urea (mg/dL) | 34.0 (26.0–42.0) | 44.0 (30.4–68.0) | 48.0 (35.0–83.0) | 81.5 (51.1–138.0) | <.001 |
| Creatinine (mg/dL) | 0.94 (0.80–1.11) | 1.16 (0.85–1.31) | 0.91 (0.79–1.41) | 1.15 (0.91–1.44) | .086 |
| Total proteins (g/L) | 64.0 (59.3–69.0) | 65.7 (59.0–71.0) | 62.7 (56.3–74.5) | 67.0 (60.9–69.7) | .75 |
| Echo | |||||
| LVDDn | 1.57 (1.43–1.72) | 2.03 (1.55–2.19) | 1.83 (0.96–2.15) | 1.13 (0.84–1.66) | .001 |
| LVSDn | 0.93 (0.80–1.04) | 1.05 (0.88–1.17) | 0.77 (0.64–1.18) | 0.63 (0.43–0.71) | <.001 |
| LA:Ao | 1.41 (1.27–1.58) | 2.45 (1.79–2.89) | 1.94 (1.30–2.93) | 1.57 (1.30–2.23) | <.001 |
| FS (%) | 36 (32–42) | 42 (39–48) | 45 (34–49) | 52 (41–59) | .001 |
| E‐max (m/s) | 0.72 (0.60–0.86) | 1.38 (0.70–1.73) | 0.97 (0.54–1.63) | 0.68 (0.45–1.25) | .001 |
| TR Vmax (m/s) | 2.34 (1.92–2.62) | 3.28 (3.12–3.45) | 3.77 (3.66–4.06) | 4.97 (4.57–5.28) | <.001 |
| TRPG (mmHg) | 21.9 (14.7–27.4) | 43.0 (38.9–47.6) | 56.8 ± (53.4–65.8) | 98.6 (83.4–111.3) | <.001 |
RDW, Red blood cell distribution width; MCV, mean corpuscular volume; WBC, white blood cell number; LVDDn, left ventricular diastolic diameter normalized for body weight; LVSDn, left ventricular systolic diameter normalized for body weight; LA, left atrial diameter; Ao, aortic diameter; FS, fractional shortening; E‐max, transmitral peak E‐wave velocity; TR Vmax, peak velocity of tricuspid regurgitation; TRPG, tricuspid regurgitation pressure gradient; n, number of dogs.
P < .05 compared with dogs without PH.
P ≤ .01 compared with dogs without PH.
P < .001 compared with dogs without PH.
P < .05 compared with dogs with mild PH.
P < .01 compared with dogs with mild PH.
P < .001 compared with dogs with mild PH.
P < .05 compared with dogs with moderate PH.
P < .01 compared with dogs with moderate PH.
P < .001 compared with dogs with moderate PH.
Values obtained from 50 dogs with TR.
Figure 1Box and whisker plots of the RDW obtained from (A) 19 healthy dogs (control), 50 dogs with myxomatous mitral valve disease without pulmonary hypertension (MMVD), 32 dogs with postcapillary pulmonary hypertension associated with myxomatous mitral valve disease (PH‐MMVD), and 26 dogs with precapillary pulmonary hypertension (precapillary PH) and (B) 59 dogs without PH (No PH) including healthy dogs and dogs with MMVD without PH, 26 dogs with mild PH (19 with PH‐MMVD and 7 with precapillary PH), 20 dogs with moderate PH (10 with PH‐MMVD and 10 with precapillary PH), and 12 dogs with severe PH (3 with PH‐MMVD and 9 with precapillary PH). Dashed lines indicate RDW reference interval. Outliers are plotted separately as white dots. Median (horizontal lines), inter quartile range (boxes) and 95% CI (whiskers) are also represented. * Statistical difference (P < .05) with control dogs. ** Statistical difference (P < .01) with dogs without PH.
Spearman's correlation coefficients between red blood cell distribution width and demographic, laboratory, and echocardiographic variables in 127 dogs
| Spearman's Correlation Coefficient |
| |
|---|---|---|
| Age | 0.327 | <.001 |
| Weight | −0.058 | .52 |
| Hematocrit | −0.225 | .011 |
| Hemoglobin | −0.227 | .010 |
| MCV | −0.077 | .39 |
| WBC | 0.319 | <.001 |
| Platelets | 0.057 | .53 |
| Urea | 0.311 | <.001 |
| Creatinine | 0.128 | .16 |
| Total proteins | −0.068 | .47 |
| LVDDn | 0.004 | .96 |
| LVSDn | −0.023 | .80 |
| LA:Ao | 0.163 | .07 |
| FS | −0.002 | .98 |
| E‐max | −0.023 | .80 |
| TR Vmax | 0.263 | .007 |
| TRPG | 0.263 | .007 |
MCV, Mean corpuscular volume; WBC, white blood cells number; LVDDn, left ventricular diastolic diameter normalized for body weight; LVSDn, left ventricular systolic diameter normalized for body weight; LA, left atrial diameter; Ao, aortic diameter; FS, fractional shortening; E‐max, transmitral peak E‐wave velocity; TR Vmax, peak velocity of tricuspid regurgitation; TRPG, tricuspid regurgitation pressure gradient.
Figure 2Scatterplots of the relationship between red blood cell distribution width (RDW) and (A) age, (B) hematocrit (Hct), (C) white blood cell number (WBC), and (D) serum urea concentration in 69 dogs without pulmonary hypertension (PH) and 58 dogs with PH, and between RDW and (E) tricuspid regurgitation pressure gradient (TRPG) in 108 dogs with tricuspid regurgitation. Dashed lines indicate RDW reference interval.
Multivariate regression equations showing the relationship between red blood cell distribution width and demographic, laboratory, and echocardiographic variables in 127 dogs
| Order of Entry | Variable | Partial | Model | Coefficient | ±SE |
| Variance Inflation Factor |
|---|---|---|---|---|---|---|---|
| 1 | Urea | 0.117 | 0.117 | 0.01 | 0.003 | <.001 | 1.338 |
| 2 | Hematocrit | 0.117 | 0.234 | −0.07 | 0.019 | <.001 | 1.038 |
| 3 | Age | 0.039 | 0.273 | 0.086 | 0.04 | .025 | 1.148 |
| 4 | WBC | 0.030 | 0.304 | 0.034 | 0.017 | .044 | 1.219 |
SE, standard error; WBC, white blood cells number.